Trials / Terminated
TerminatedNCT01381666
Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the present work is to explore and compare the diagnostic quality of sputum specimens obtained by BAL, induction with hypertonic saline (3%), and induction with INS316 in patients diagnosed with interstitial lung diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INS316 solution for inhalation | inhalation via nebulizer given for 2 doses for 60 minutes each |
| DRUG | hypertonic saline 3% sodium chloride solution | inhalation via nebulizer given for 2 doses for 60 minutes each |
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2004-04-01
- Completion
- 2004-04-01
- First posted
- 2011-06-27
- Last updated
- 2015-10-29
Source: ClinicalTrials.gov record NCT01381666. Inclusion in this directory is not an endorsement.